HK Stock Market Move | Hansoh Pharma (03692) surged nearly 6% after its performance report. Net profit in the first half of the year increased by 15% year-on-year, with innovative drug revenue accounting for over 80%.

HANSOH PHARMA (03692) rose nearly 6% after its performance announcement, with a 5.67% increase to HK$39.16 per share and a turnover of HK$176 million. In terms of news, HANSOH PHARMA released its interim results, with the group achieving a revenue of RMB 7.434 billion, a 14.27% increase year-on-year; the profit attributable to the owners of the parent company was RMB 3.135 billion, a 15.02% increase year-on-year; earnings per share were RMB 0.53, and a mid-term dividend of HK$0.2316 per share is proposed. The company has seven innovative drugs generating sales revenue in China. In the first half of 2025, sales revenue from innovative drugs and collaborative products amounted to approximately RMB 6.145 billion, accounting for about 82.7% of total revenue. It is worth noting that in June of this year, HANSOH PHARMA announced granting overseas exclusive license for HS-20094, a recombinant GLP-1/GIP dual receptor agonist, with a potential total amount exceeding $2 billion. The company mentioned in its financial report that clinical studies have been conducted on over 1,000 subjects, and HS-20094 is currently progressing actively in Phase III clinical studies for obesity or overweight. The company received an $80 million upfront payment in July.